Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not
Daniel A González-Padilla 1 , José Daniel Subiela 2
While PARP inhibitors such as rucaparib and olaparib have shown activity in metastatic castration-resistant prostate cancer, they have failed to show a clear improvement in hard outcomes such as overall survival or quality of life.
Because of methodological limitations, we suggest caution before implementing these treatments in routine clinical practice; offering them to patients without a BRCA1/2 mutation is probably inappropriate.
CITATION Eur Urol. 2023 May 25;S0302-2838(23)02824-5. doi: 10.1016/j.eururo.2023.05.017